Jiangsu Realshare Bio-Tech Co., Ltd. is a high-tech enterprise wholly owned by Shenzhen Realshare Bio-Tech Co., Ltd., which integrates the R&D, manufacturing and marketing of pharmaceutical intermediates, APIs and formulations.
Based on the unique advantages of β-lactamase inhibitor API and intermediates production base, who has abundant experience for the reactions like Azidation, metal catalysis, Chlorination, deep cool, ultra-temperature, Ammonification etc., we develop Antiviral, Cardiovascular, Anti-obesity and other fields of characteristic intermediate, API and drugs, and provide high added value and cost-effective products to our domestic and overseas customers.
At the same time, we possess the leading core technologies on continuous flow micro-reaction, asymmetric synthesis, enzyme catalysis and others. We support and deeply participate in R&D of generic and innovative drugs with high clinical value and core technology, aim at a quick launch of drugs.
Realshare keep the strategy of both internal development and external expand: focus on research and development ourselves; also deepen the industry ecology by extensional acquisition.